Cefotetan Therapy for Escherichia Coli Infections

Exclusion Criteria

• •Allergy to cefotetan.
• •History of cephalosporin-associated hemolytic anemia.
• •Allergy to ertapenem or meropenem (among patients with ESBL E. coli infections).
• •Allergy to ceftriaxone (among patients with non-ESBL E. coli infections). Includes allergy to antibiotics with a similar structure expected to confer cross reactivity to ceftriaxone (cefotaxime, cefpodoxime, ceftazidime).
• •Admission within 30 previous days.
• •Any bacteremia with the same organism in the previous 90 days.
• •Pregnant or breastfeeding.
• •Moderately to severely immunocompromised, including solid organ or stem cell transplant, hematologic malignancy, active chemotherapy.
• •Admission with neutropenic fever.
• •Severe illness, including shock and/or intensive care unit admission.
• •Inability to complete at least 72 hours of appropriate parenteral therapy, including at least 1 dose cefotetan for patients randomized to the treatment arm or at least 1 dose of appropriate parenteral therapy following randomization for patients assigned to the standard of care arm.